Zealand Pharma A/S (ZLDPF) to Release Quarterly Earnings on Thursday

Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report) is expected to post its Q1 2025 quarterly earnings results before the market opens on Thursday, May 8th. Analysts expect Zealand Pharma A/S to post earnings of ($0.77) per share and revenue of $248.61 million for the quarter.

Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.67) EPS for the quarter, topping the consensus estimate of ($0.77) by $0.10. The business had revenue of $1.14 million during the quarter, compared to analyst estimates of $248.61 million. Zealand Pharma A/S had a negative net margin of 1,725.03% and a negative return on equity of 15.24%. On average, analysts expect Zealand Pharma A/S to post $-2 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Zealand Pharma A/S Stock Performance

Zealand Pharma A/S stock traded down $1.11 during midday trading on Tuesday, reaching $63.27. 601 shares of the stock traded hands, compared to its average volume of 995. The firm has a fifty day moving average price of $71.40 and a two-hundred day moving average price of $92.73. Zealand Pharma A/S has a fifty-two week low of $57.97 and a fifty-two week high of $141.74. The firm has a market cap of $4.49 billion, a price-to-earnings ratio of -26.81 and a beta of 0.92. The company has a current ratio of 35.49, a quick ratio of 35.49 and a debt-to-equity ratio of 0.03.

Wall Street Analyst Weigh In

ZLDPF has been the topic of a number of recent analyst reports. Cantor Fitzgerald upgraded shares of Zealand Pharma A/S to a "strong-buy" rating in a research note on Tuesday, January 21st. William Blair upgraded shares of Zealand Pharma A/S from a "hold" rating to a "strong-buy" rating in a research report on Friday, March 7th.

About Zealand Pharma A/S

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.